Therapy with NEMOS®
Clinicians' information about NEMOS®
How is NEMOS® used?
t-VNS® treatment uses the transcutaneous vagus nerve stimulator. NEMOS® consists of a stimulation unit and a dedicated ear electrode.
The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The impulses are transferred via ear electrode through the skin to a branch of the vagus nerve.
Patients carry out the t-VNS® treatment autonomously. There is no need of hospitalization. The routine monitoring of the treatment is also accomplished on an outpatient procedure. Patients treat themselves with t-VNS® in sessions lasting approximately 4 hours per day.
Users can regulate and adapt the stimulation intensity according to their individual sensitivity. This can change from day to day, due to variations in skin parameters like humidity or fat content. Important is that the stimulation is noticeable. The patient should feel a tingling sensation at the contact point in the concha.
Basically, patients can carry on with their usual everyday activities during the stimulation session, so NEMOS® is easy to integrate into the patient’s daily routine.
How effective is t-VNS®?
Like most pharmaceutical and neuromodulatory treatments for epilepsies, therapy with NEMOS® is not an acute therapy. For patients who respond to therapy with NEMOS® the anticonvulsive effect may occur with a latency of some weeks to a few months.
Which side effects may occur?
When using t-VNS®® treatment, local side effects caused by the stimulation, such as itching, paraesthesia in the area of the outer auricle, pain, redness, pressure marks and skin lesion may occur at the point of stimulation.
The stimulation of the vagus nerve may affect the autonomic nervous system. This may manifest in the form of symptoms such as headaches, nausea or vertigo.
As with any other treatment based on drugs or neurostimulation, t-VNS®® treatment may lead to an increase in seizures. This involves increases in one or more of the following: seizure frequency (series of seizures up to and including, albeit rarely, status epilepticus), severity and duration. A change in the character of seizures is also possible – they may, for example, begin to occur during the day rather than at night.
These side effects will generally subside soon after Stimulation is stopped.
- Additional therapy option
- With Nemos there is another promising and easy therapy option available for patients suffering from epilepsies.
- Easy patient care
- Patients carry out the treatment autonomously. There’s no need for additional or longer doctors’ appointments.
- No surgical intervention
- t-VNS® therapy with Nemos provides targeted stimulation of the vagus nerve, without the risks of a surgical intervention.
- Minor side effects
- t-VNS® is a therapeutic alternative with minor side effects. Potential side effects include itching, dysaesthesia, and local pain at the stimulation site. These side effects usually disappear soon after stopping the stimulation.*
- Trial period of 6 months